We are live on ! Find out more
ALDR

Alder Biopharmaceuticals
ALDR

Delisted

ALDR was delisted on the 21st of October, 2019.

Back to rankings

75 hedge funds and large institutions have $383M invested in Alder Biopharmaceuticals in 2014 Q4 according to their latest regulatory filings, with 21 funds opening new positions, 22 increasing their positions, 25 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

600% more first-time investments, than exits

New positions opened: 21 | Existing positions closed: 3

200% more funds holding in top 10

Funds holding in top 10: 1 → 3 (+2)

135% more capital invested

Capital invested by funds: $163M → $383M (+$220M)

32% more funds holding

Funds holding: 57 → 75 (+18)

12% less repeat investments, than reductions

Existing positions increased: 22 | Existing positions reduced: 25

Holders
75
Holders Change
+18
Holders Change %
+31.58%
% of All Funds
2%
Holding in Top 10
3
Holding in Top 10 Change
+2
Holding in Top 10 Change %
+200%
% of All Funds
0.08%
New
21
Increased
22
Reduced
25
Closed
3
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

1
Citadel Advisors
Citadel Advisors
Florida
+$7.2M
2
BFA
BlackRock Fund Advisors
California
+$7.08M
3
Goldman Sachs
Goldman Sachs
New York
+$3.81M
4
CAM
Cormorant Asset Management
Massachusetts
+$1.79M
5
Vanguard Group
Vanguard Group
Pennsylvania
+$1.58M

Top Sellers

1
PHS
PFM Health Sciences
California
-$12.6M
2
Fidelity Investments
Fidelity Investments
Massachusetts
-$7.17M
3
PC
PointState Capital
New York
-$3.59M
4
CCM
Cadian Capital Management
New York
-$1.52M
5
Jennison Associates
Jennison Associates
New York
-$1.4M
Name Holding Trade Value Shares
Change 		Change in
Stake
California Public Employees Retirement System
51
California Public Employees Retirement System
California
$321K +$198K +11,032 New
D.E. Shaw & Co
52
D.E. Shaw & Co
New York
$285K +$176K +9,810 New
Point72 Asset Management
53
Point72 Asset Management
Connecticut
$271K +$167K +9,300 New
Citigroup
54
Citigroup
New York
$227K -$1.08M -60,280 -89%
Morgan Stanley
55
Morgan Stanley
New York
$226K +$118K +6,561 +540%
LTFS
56
Ladenburg Thalmann Financial Services
Florida
$225K +$124K +6,900 +812%
PIM
57
Partner Investment Management
California
$216K -$291K -16,238 -69%
Wells Fargo
58
Wells Fargo
California
$211K -$377K -20,982 -74%
RhumbLine Advisers
59
RhumbLine Advisers
Massachusetts
$205K +$127K +7,050 New
MLICM
60
Metropolitan Life Insurance Company (MetLife)
New York
$201K +$124K +6,911 New
NFA
61
Nationwide Fund Advisors
Ohio
$181K – – –
AIG
62
American International Group
New York
$146K -$3.55K -198 -4%
SG Americas Securities
63
SG Americas Securities
New York
$127K +$78.6K +4,379 New
AllianceBernstein
64
AllianceBernstein
Tennessee
$113K -$23.3K -1,300 -25%
BJ
65
BlackRock Japan
Japan
$49K -$40.2K -2,240 -57%
PCM
66
Prelude Capital Management
New York
$32K +$19.7K +1,100 New
TRCT
67
Tower Research Capital (TRC)
New York
$21K +$13.2K +733 New
Barclays
68
Barclays
United Kingdom
$19K -$16.2K -900 -58%
Bank of America
69
Bank of America
North Carolina
$17K -$68.2K -3,800 -86%
Creative Planning
70
Creative Planning
Kansas
$17K – – –
CSS
71
Cubist Systematic Strategies
Connecticut
$15K +$9.08K +506 New
MAA
72
Managed Account Advisors
New Jersey
$12K -$377 -21 -5%
Manulife (Manufacturers Life Insurance)
73
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$183 +$21.7K +1,211 +24%
CCM
74
Cadian Capital Management
New York
– -$1.52M -120,000 Closed
Alyeska Investment Group
75
Alyeska Investment Group
Illinois
– -$722K -56,937 Closed
1 2
3
4

ALDR Hedge Fund Activity: Q4 2014 in Review

75 of the 3,749 institutional investors tracked by Wall St. Rank reported a position in Alder Biopharmaceuticals (ALDR) for Q4 2014, worth a combined $383M — up 135% from $163M a quarter earlier.

Buyers outnumbered sellers: 21 funds opened new ALDR positions and 3 closed out — a net gain of 18 holders — while 22 added to existing stakes and 25 trimmed.

The largest buyer was Citadel Advisors, adding an estimated $7.2M. The largest seller was PFM Health Sciences, cutting an estimated $12.6M.

  • 75 institutional investors held Alder Biopharmaceuticals (ALDR) as of Q4 2014, up from 57 in Q3 2014.
  • Funds reported $383M of Alder Biopharmaceuticals stock for Q4 2014, up 135% quarter-over-quarter.
  • 21 funds opened new Alder Biopharmaceuticals positions in Q4 2014 and 3 closed out, a net change of +18 holders.
  • The largest Alder Biopharmaceuticals buyer in Q4 2014 was Citadel Advisors, an estimated $7.2M added.
  • The largest Alder Biopharmaceuticals seller in Q4 2014 was PFM Health Sciences, an estimated $12.6M sold.

Based on aggregated 13F filings for Q4 2014.